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Bloodstream Infections and Clinical Significance of Healthcare-
associated Bacteremia: A Multicenter Surveillance Study  
in Korean Hospitals
Recent changes in healthcare systems have changed the epidemiologic paradigms in 
many infectious fields including bloodstream infection (BSI). We compared clinical 
characteristics of community-acquired (CA), hospital-acquired (HA), and healthcare-
associated (HCA) BSI. We performed a prospective nationwide multicenter surveillance 
study from 9 university hospitals in Korea. Total 1,605 blood isolates were collected 
from 2006 to 2007, and 1,144 isolates were considered true pathogens. HA-BSI 
accounted for 48.8%, CA-BSI for 33.2%, and HCA-BSI for 18.0%. HA-BSI and HCA-
BSI were more likely to have severe comorbidities. Escherichia coli was the most 
common isolate in CA-BSI (47.1%) and HCA-BSI (27.2%). In contrast, Staphylococcus 
aureus (15.2%), coagulase-negative Staphylococcus (15.1%) were the common 
isolates in HA-BSI. The rate of appropriate empiric antimicrobial therapy was the 
highest in CA-BSI (89.0%) followed by HCA-BSI (76.4%), and HA-BSI (75.0%). The 30-
day mortality rate was the highest in HA-BSI (23.0%) followed by HCA-BSI (18.4%), 
and CA-BSI (10.2%). High Pitt score and inappropriate empirical antibiotic therapy 
were the independent risk factors for mortality by multivariate analysis. In conclusion, 
the present data suggest that clinical features, outcome, and microbiologic features 
of causative pathogens vary by origin of BSI. Especially, HCA-BSI shows unique clinical 
characteristics, which should be considered a distinct category for more appropriate 
antibiotic treatment.
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INTRODUCTION
Bloodstream infection (BSI) is potentially life-threatening con-
dition with a case fatality rate of 30-40% (1). If BSI is clinically 
suspected, clinicians should choose antibiotics based on the 
type of infection, underlying disease, patient age, infecting patho-
gen, and site of acquisition of infection (2). 
  BSI can be classified as community-acquired (CA), hospital-
acquired (HA), or healthcare–associated (HCA) depending on 
the site of acquiring infection and risk factors. Of 3 epidemio-
logic categories, HCA-BSI is a recently developed category that 
is traditionally classified as CA-BSI (3-5).
  Clinically, the characteristics of HA-BSI can be separated from 
those of CA-BSI in many factors such as pathogen distribution, 
type of infection and their susceptibility patterns. Staphlylococ-
cus and catheter-related infection were predominant in HA-BSI, Son JS, et al.  •  Bloodstream Infection According to the Epidemiologic Type of Infection
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while Escherichia coli and urinary tract infection were generally 
predominant in CA-BSI (6-8). With regard to HCA-BSI, previous 
studies showed that the clinical characteristics were not similar 
to those of CA-BSI (3, 5, 9). And the susceptibility patterns of 
HCA-BSI were similar to those of HA-BSI (5, 9). Generally, the 
concept of HCA-BSI has been accepted to be an independent 
epidemiologic category of BSI. However, so far the detailed data 
of clinical characteristics of HCA-BSI were not sufficient. Also, 
the independent risk factors for mortality of each BSI have not 
been compared yet. 
  In this study, we compared clinical characteristics of 3 BSI 
groups including HCA-BSI, instead of investigating one patho-
gen or one source. And we performed additional analysis to 
evaluate risk factors for mortality according to the epidemio-
logic type of infection.
MATERIALS AND METHODS
Study design and data collection
This study was a prospective nationwide surveillance of BSI in  
9 university hospitals in various regions of Korea from October 
2006 to September 2007. The participating institutions included 
Kyunghee East-West Neo Medical Center (800-bed, Seoul), Sam-
sung Medical Center (1,270-bed, Seoul), Kangbuk Samung Hos-
pital (620-bed, Seoul), Konkuk University Hospital (820-bed, 
Seoul), Kyungpook National University Hospital (850-bed, Dae-
gu), Keimyung University Dongsan Medical Center (910-bed, 
Daegu), Chungnam National University Hospital (980-bed, Dae-
jeon), Chonnam National University Hospital (850-bed, Gwangju), 
and Jeju National University Hospital (300-bed, Jeju). The fol-
lowing data were collected from all cases of BSI; demographic 
information, underlying disease, comorbid conditions, micro-
biological data, sources of infection, and other important clini-
cal parameters at the time of infection. The main clinical out-
come was measured by the 30-day mortality rate.
Study population
All blood isolates during the study period from the participating 
hospitals were reviewed for clinical significance. Cases that show- 
ed clinical features of Systemic Inflammatory Response Syn-
drome (SIRS) were included in this study. SIRS was defined by 
the presence of at least two of the following signs and symptoms: 
tachycardia (pulse rate >90 beats/min); tachypnea (respiratory 
rate >20/min); fever (body temperature >38°C) or hypothermia 
(body temperature <36°C); leukocytosis (white blood cell count 
>12,000 cells/μL) or leukopenia (white blood cell count <4,000 
cells/μL) (10). The site of infection causing BSI was estimated 
by infectious disease specialist at participating institutions. All 
underlying diseases and comorbid conditions for each patient 
were included in the analysis. And only the first bacteremic epi-
sode for each patient was included.
Definitions
BSI cases were classified as CA, HA, or HCA depending on the 
site of acquiring infection and risk factors. HA-BSI was defined 
if blood culture was positive >48 hr from admission or who had 
been discharged from an acute care hospital within the past 10 
days. HCA-BSI was defined if patients had a history of hospital-
ization for 2 or more days in the previous 90 days; receipt of in-
travenous (IV) medication or home wound care in the previous 
30 days; receipt of hemodialysis; or residence in a nursing home 
or long-term care facility (3, 5, 9 ). CA-BSI was defined if patients 
had the first positive blood culture <48 hr after admission and 
who did not have any risk factors for HCA-BSI. Neutropenia was 
defined as an absolute neutrophil count below 500/μL. Cortico-
steroid use was noted only if the patient had recently received 
the equivalent of 30 mg of prednisone daily for at least seven 
days, or 20 mg each day for 14 days. Receipt of immunosuppres-
sant was defined as use of any immunosuppressive drug (e.g., 
cyclosporine, antineoplastic chemotherapy) in the previous 30 
days. Prior antibiotic use was defined as use of antimicrobial 
agent for >3 days in the previous 30 days. High alcohol uptake 
was noted if the patient had ingested >100 g of alcohol every day. 
Severe sepsis was defined as sepsis associated with the presence 
of at least one or more following signs of organ dysfunction; met-
abolic acidosis, acute alteration in mental status, oliguria, and/
or adult respiratory distress syndrome (11). The Pitt score was 
calculated within 2 days prior to or on the day of first positive 
blood culture on the basis of 5 parameters (fever, hypotension, 
mechanical ventilation, cardiac arrest, and mental status) (12). 
The initial empirical antibiotic therapy was considered ‘appro-
priate’ if the initial antibiotics, which were administered within 
24 hr after acquisition of blood culture samples, included at least 
one antibiotic that was active in vitro and when the dosage and 
route of administration confirmed with current medical stan-
dards. Otherwise, initial antibiotic therapy was considered ‘in-
appropriate’ (13). The ‘improvement’ of treatment outcome was 
defined as partial resolution of presenting signs and test results 
(e.g., fever, elevated leukocyte) of the infection (14).
Microbiological tests
All isolates identified from each hospital were transported to 
the central laboratory of the Asian-Pacific Research Foundation 
for Infectious Diseases (ARFID), Seoul, Republic of Korea. Anti-
biotic susceptibility testing was performed in this laboratory 
using the modified broth microdilution method. Minimum in-
hibitory concentration (MIC) breakpoints and quality control 
protocols were used according to the standards established by 
the Clinical and Laboratory Standards Institute (CLSI) (15). 
Statistical analysis
Student’s t-test was used to compare continuous variables (age 
and PITT score), and chi-square or Fisher’s exact test was used Son JS, et al.  •  Bloodstream Infection According to the Epidemiologic Type of Infection
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to compare categorical variables (underlying diseases, comor-
bid conditions, microorganism distributions, sources of infec-
tion, and treatment outcome). For pairwise comparisons, 3×2 
table (3 epidemiologic type of BSI) was broken down into three 
2×2 tables (CA vs. HCA, HA vs. HCA, CA vs. HA). To determine 
the independent risk factors for mortality, a multiple logistic re-
gression analysis was used. P values <0.05 were considered sta-
tistically significant. The SPSS for Windows software package 
(version 11.5) was used for this analysis.
Ethics
This study was performed with an exemption of the deliberation 
permitted by the Institutional Review Board at East-West Neo 
Medical Center (2009-075). All data collected from this study 
were kept confidential.
RESULTS
Patient characteristics
A total of 1,605 blood isolates were obtained from 9 hospitals 
between October 2006 and September 2007. Of these 1,605 iso-
lates, 461 isolates (28.7%) were not considered true pathogens 
because there were no compatible clinical features of SIRS. 
Among 1,144 isolates included in the study, HA-BSI accounted 
for 48.8% (558/1,144), CA-BSI for 33.2% (380/1,144), and HCA-
BSI for 18.0% (206/1,144).
  The mean age was the highest in patients with CA-BSI (57.0± 
20.7), followed by HCA-BSI (53.7±20.7), and HA-BSI (47.3±23.7) 
(Table 1). With regard to underlying diseases, solid tumor and 
hematologic malignancy was the most common disease in HCA-
BSI group (54.9%) and HA-BSI group (24.6%), respectively. Com-
pared with other groups, patients with CA-BSI were significant-
ly less likely to have solid tumor (24.2%, 32.4%, 54.9% in CA-BSI, 
HA-BSA, and HCA-BSI, P<0.005, respectively) and hematologic 
malignancy (3.4%, 24.6%, 16.0% in CA-BSI, HA-BSA, and HCA-
BSI, P<0.005, respectively). 
  Patients with HA-BSI or HCA-BSI were more likely to have 
severe comorbidities (neutropenia, receipt of steroids, receipt 
of immunosuppressant, or prior antibiotic use) compared with 
CA-BSI group (for neutropenia, 8.9%, 28.3%, 25.2% in CA-BSI, 
HA-BSI, and HCA-BSI, P<0.005; for receipt of steroid, 4.7%, 28.1%, 
24.3%, P<0.005; for receipt of immunosuppressant, 9.2%, 33.2%, 
31.6%, P<0.005; for prior antibiotic use, 7.1%, 54.7%, 14.6%, re-
spectively, P<0.005).
Pathogen distribution
Of all BSI isolates, 59.2% were Gram-negative aerobes, and 38.9% 
were Gram-positive aerobes. As a total, E. coli (27.8%) was the 
most common isolate followed by Klebsiella pneumoniae (13.6 
%), S. aureus (12.4%), coagulase-negative Staphylococcus (9%), 
Enterococcus species (7.1%) (Table 2). The prevalence of E. coli 
was the highest in CA-BSI group, and the incidence of E. coli var-
ied by type of BSI (47.1%, 14.9%, 27.2% in CA-BSI, HA-BSA, and 
HCA-BSI, respectively, P<0.005). Of CA-BSI isolates, the inci-
dence of Gram-negative aerobes (70.5%) was more than two 
times higher than that of Gram-positive aerobes (28.2%). E. coli 
Table 1. Patient characteristics of bloodstream infection by epidemiologic type of infection
Characteristics
No. (%) P value
CA-BSI (n=380) 
No. (%)
HA-BSI (n=558) 
No. (%)
HCA-BSI (n=206)
No. (%)
CA vs. HCA HA vs. HCA CA vs. HA
Demographics
   Age (Mean year±SD)
   Male sex
57.0±20.7
 184 (48.4)
47.3±23.7
339 (60.8)
53.7±20.7
131 (63.6)
  0.251
<0.001
  0.001
  0.474
<0.001
<0.001
Underlying disease
   Solid tumor
   Hematologic malignancy
   Diabetes mellitus
   Chronic liver disease
   Chronic renal disease
   Congestive heart failure
   Stroke 
   92 (24.2)
 13 (3.4)
   75 (19.2)
   59 (15.5)
 16 (4.2)
   3 (0.8)
 16 (4.2)
181 (32.4)
137 (24.6)
  96 (17.2)
54 (9.7)
37 (6.6)
12 (2.2)
28 (5.0)
113 (54.9)
  33 (16.0)
  35 (17.0)
  38 (18.4)
11 (5.3)
  2 (1.0)
  8 (3.9)
<0.001
<0.001
  0.461
  0.364
  0.534
  0.820 
  0.849
<0.001
  0.012
  0.944
  0.001
  0.514
  0.281
  0.511
  0.006
<0.001
  0.376
  0.007
  0.115
  0.103
  0.566
Comorbid condition
   Neutropenia
   Receipt of steroids 
   Receipt of immunosuppressant
   Prior antibiotic use
   History of transplantation
   High alcohol uptake
   Smoking
   Urinary catheter
   Central venous catheter
   Intra-abdominal catheter
 34 (8.9)
 18 (4.7)
 35 (9.2)
 27 (7.1)
 11 (2.9)
 26 (6.8)
 27 (7.1)
0 (0)
0 (0)
0 (0)
158 (28.3)
157 (28.1)
185 (33.2)
305 (54.7)
51 (9.1)
14 (2.5)
41 (7.3)
185 (33.1)
336 (60.2)
134 (24.0)
  52 (25.2)
  50 (24.3)
  65 (31.6)
  30 (14.6)
  5 (2.4)
  5 (2.4)
  8 (3.9)
  38 (18.4)
  58 (28.2)
  29 (14.1)
<0.001
<0.001
<0.001
  0.004
  0.740
  0.023
  0.116
NA
NA
NA
  0.399
  0.286
  0.676
  0.000
  0.002
  0.949
  0.083
<0.001
<0.001
  0.003
<0.001
<0.001
<0.001
<0.001
<0.001
  0.001
  0.888
NA
NA
NA
CA, community-acquired; HA, hospital-acquired; HCA, healthcare-associated; BSI, bloodstream infection; NA, not available.Son JS, et al.  •  Bloodstream Infection According to the Epidemiologic Type of Infection
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(47.1%) and K. pneumoniae (12.6%) represent more than half 
of the isolates in CA-BSI followed by S. aureus (7.4%), Streptococ-
cus viridans group (5.0%). Of HA-BSI isolates, 49.1% were Gram-
negative aerobes, and 48.0% were Gram-positive aerobes. The 
most common isolate of HA-BSI was S. aureus (15.2%) followed 
by coagulase-negative Staphylococcus (15.1%), and E. coli (14.9 
%). The pattern of isolates in HCA-BSI was more similar to that 
in CA-BSI than that in HA-BSI. Of HCA-BSI isolates, Gram-neg-
ative aerobes (65.5%) were more common than Gram-positive 
aerobes (34.0%) like CA-BSI. However, isolate distributions of 
CA-BSI and HCA-BSI group were not identical. While E. coli 
(47.1% vs. 27.2% in CA-BSI vs. HCA-BSI, P<0.001) and Strepto-
coccus pneumoniae (3.9% vs. 1.0% in CA-BSI vs. HCA-BSI, P= 
0.04) were recovered more frequently in CA-BSI, S. aureus (7.4% 
vs. 14.1% in CA-BSI vs. HCA-BSI, P=0.009) and P. aeruginosa 
(2.9% vs. 7.8% in CA-BSI vs. HCA-BSI, P=0.007) were more prev-
alent in HCA-BSI.
  With regard to resistant pathogens, extended spectrum beta-
lactamase (ESBL)-producing E. coli was most frequently recov-
ered in patients with HA-BSI (31.3%), followed by HCA-BSI (14.2 
%) and CA-BSI (3.3%) (HA-BSI vs. CA-BSI, P<0.001; HA-BSI vs. 
HCA-BSI, P=0.021; HCA-BSI vs. CA-BSI, P=0.002). ESBL-pro-
ducing K. pneumoniae was common in patients with HA-BSI 
(18.9%), followed by HCA-BSI (14.7%) and CA-BSI (4.1%). Al-
though, it did not show the statistical difference for the preva-
lence of ESBL-producing K. pneumoniae (HA-BSI vs HCA-BSI, 
P=0.593; HCA-BSI vs. CA-BSI, P=0.092) except between HA-BSI 
and CA-BSI (P=0.018). Methicillin-resistant Staphylococcus au-
reus (MRSA) was higher in HA-BSI (69.4%), compared with HCA-
BSI (31.0%, P<0.001) and CA-BSI group (17.8%, P<0.001).
Table 2. Microorganism distribution of bloodstream infection by epidemiologic type of infection
Microorganisms
No. (%) P value
CA-BSI (n=380)
No. (%)
HA-BSI (n=558)
No. (%)
HCA-BSI (n=206)
No. (%)
CA vs. HCA HA vs. HCA CA vs. HA
Gram positive aerobes 107 (28.2) 268 (48.0)    70 (34.0) 0.142 <0.001 <0.001
   Staphylococcus aureus 
   MRSA
   CNS species 
   Enterococcus species
   Streptococcus viridans group 
   Streptococcus pneumoniae 
   Streptococcus agalactiae 
   Other Gram positive aerobes*
28 (7.4)
5/28 [17.8]
10 (2.6)
12 (3.2)
19 (5.0)
15 (3.9)
  7 (1.8)
16 (4.2)
  85 (15.2)
59/85 [69.4]
 84 (15.1)
 60 (10.8)
12 (2.2)
 7 (1.3)
 6 (1.1)
14 (2.5)
   29 (14.1)
9/29 [31.0]
   9 (4.4)
   9 (4.4)
   8 (3.9)
   2 (1.0)
0 (0)
 13 (6.3)
0.009
0.247
0.257
0.451
0.538
0.040 
0.050 
0.263 
0.691
<0.001
<0.001
0.006
0.183
0.747
0.135
0.011 
<0.001
<0.001
<0.001
<0.001
0.017
0.007
0.324
0.146 
Gram negative aerobes 268 (70.5) 274 (49.1)  135 (65.5) 0.213 <0.001 <0.001
   Escherichia coli         
   ESBL (+)
   Klebsiella pneumoniae 
   ESBL (+)
   Pseudomonas aeruginosa 
   Acinetobacter species 
   Enterobacter cloacae 
   Other Gram negative aerobes
†
179 (47.1)
6/179 [3.3]
  48 (12.6)
2/48 [4.1]
11 (2.9)
  5 (1.3)
  5 (1.3)
20 (5.2)
 83 (14.9)
26/83 [31.3]
 74 (13.3)
14/74 [18.9]
36 (6.5)
27 (4.8)
13 (2.3)
41 (7.3)
   56 (27.2)
8/56 [14.2]
   34 (16.5)
5/34 [14.7]
 16 (7.8)
   4 (1.9)
   6 (2.9)
 19 (9.2)
<0.001
0.002
0.197
0.092
0.007
0.556
0.174
0.066 
<0.001
0.021
0.254
0.593
0.522
0.072
0.646
0.392 
<0.001
<0.001
0.778
0.018
0.014
0.004
0.266
0.203 
Anaerobes   3 (0.8)   3 (0.5)    1 (0.5) 0.669 0.929 0.669
Fungi    2 (0.5) 13 (2.3) 0 (0) 0.297 0.027 0.031
*Other Gram positive aerobes, Streptococcus pyogenes, and other group Streptococcus; 
†Other Gram negative aerobes,Klebsiella oxytoca, Serratia marcescens, Burkholderia 
cepacia, Proteus mirabilis, Citrobacter freundii, Morganella morganii, Enterobacter aerogenes, Haemophilus influenazae, and other.
CA, community-acquired; HA, hospital-acquired; HCA, healthcare-associated; BSI, bloodstream infection; ESBL, extended spectrum β-lactamase; MRSA, methicillin-resistant 
Staphylococcus aureus; CNS, coagulase-negative Staphylococcus.
Table 3. Primary sources of bloodstream infection by epidemiologic type of infection
Source of infection
Frequency distribution P value
CA-BSI (n=380)
No. (%)
HA-BSI (n=558)
No. (%)
HCA-BSI (n=206)
No. (%)
CA vs. HCA HA vs. HCA CA vs. HA
Primary bacteremia 22 (5.7) 297 (53.2) 82 (39.8) <0.001   0.001  <0.001
Intra-abdominal infection 116 (30.5)   98 (17.6) 56 (27.2)   0.396    0.003  <0.001
Urinary tract infection 119 (31.3) 32 (5.7) 30 (14.2) <0.001 <0.001 <0.001
Pneumonia   42 (11.1)   79 (14.2) 29 (14.1)   0.284    0.978    0.164 
Soft tissue infection 13 (3.4) 15 (2.7) 6 (2.9)   0.740    0.866    0.517 
Other*   68 (17.9) 37 (6.6) 3 (1.5) NA NA NA
*Other, Bone and joint infection, endocarditis, central nervous system infection, and other.
CA, community-acquired; HA, hospital-acquired; HCA, healthcare-associated; BSI, bloodstream infection; NA, not available.Son JS, et al.  •  Bloodstream Infection According to the Epidemiologic Type of Infection
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Primary infection
The primary infections causing BSI significantly varied by type 
of BSI. The most common primary infection of CA-BSI were uri-
nary tract infection (UTI) (31.3%) and intra-abdominal infec-
tion (30.5%) (Table 3). In contrast, primary bacteremia (53.2%) 
was the most common in HA-BSI group followed by intra-ab-
dominal infection (17.6%), and pneumonia (14.2%). The most 
common primary infection of HCA-BSI was primary bactere-
mia (39.8%) like HA-BSI, and followed by intra-abdominal in-
fection (27.2%) and UTI (14.2%). 
Clinical outcomes
Severity index on admission measured by Pitt bacteremia score 
in patients with HCA-BSI (2.2±3.0) was significantly higher than 
that in CA-BSI group (1.5±2.6) (P=0.012) (Table 4). And, the in-
cidence of severe sepsis in HCA-BSI group (36.9%) was also high-
er than that in CA-BSI (23.4%, P=0.001). 
  The rate of appropriate empirical antibiotic therapy was the 
highest in CA-BSI group (89.0%), followed by HCA-BSI (76.4%), 
and HA-BSI group (75.0%). Initial clinical improvement rate was 
more frequently observed in CA-BSI group (85.7%) than in HCA-
BSI (68.64%, P<0.001) and HA-BSI group (68.5%, P<0.001).
  The overall 30-day mortality rate in all patients with BSI was 
18% (193/1,144). Mortality rate was significantly lower in CA-
BSI group (10.2%) than in HCA-BSI (18.4%, P=0.007), and HA-
BSI group (23.0%, P<0.001). Although, no significant difference 
was seen in mortality rate between HA-BSI and HCA-BSI group 
(P=0.188).
Risk factors for mortality
By univariate analysis, high Pitt score (>4), severe sepsis, inap-
propriate empirical antibiotic therapy were the common risk 
factors for all patients with BSI (Table 5). For demographics and 
comorbidities, old age (≥65 yr), underlying solid tumor, stroke, 
high alcohol uptake, neutropenia were the significant risk fac-
tors for mortality in CA-BSI group. In HA-BSI group, old age (≥65 
yr), underlying congestive heart failure, receipt of immunosup-
pressant, prior antibiotic use, history of transplantation were the 
Table 4. Clinical outcome of bloodstream infection by epidemiologic type of infection
Characteristic
Frequency distribution P value
CA-BSI (n=380)
No. (%)
HA-BSI (n=558)
No. (%)
HCA-BSI (n=206)
No. (%)
CA vs. HCA HA vs. HCA CA vs. HA
Severity on admission
   PITT score (Mean±SD)
   Severe sepsis
1.5±2.6
  89 (23.4)
2.1±2.5
162 (29.0)
2.2±3.0
  76 (36.9)
  0.012  
  0.001  
1.000 
0.037 
  0.003 
  0.057 
Appropriate empirical antibiotics 341 (89.0) 429 (75.0) 160 (76.4) <0.001 0.687  <0.001
Treatment outcome
   Improvement (7 days)
   Death, all cause (30 days) 
306 (85.7)
  36 (10.2)
367 (68.5)
122 (23.0)
131 (68.6)
  35 (18.4)
<0.001
  0.007
0.976 
0.188
<0.001
<0.001
CA, community-acquired; HA, hospital-acquired; HCA, healthcare-associated; BSI, bloodstream infection.
Table 5. Risk factors associated with 30 day mortality in bloodstream infection by epidemiologic type of infection
Risk factors
CA-BS I HA-BSI
 
HCA-BSI
Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age, ≥65 yr 2.44 (1.20-4.96) 0.011 1.62 (1.04-2.51) 0.030 1.87 (0.88-3.96)   0.095
Male sex 0.7 (0.35-1.40) 0.313 0.85 (0.56-1.3) 0.469 0.65 (0.29-1.45)   0.292
Solid tumor 2.47 (1.21-5.05) 0.011 1.23  (0.80-1.88) 0.337 1.89  (0.88-4.06)   0.099
Congestive heart failure 0.89 (0.86-0.93) 0.558 3.44 (0.98-12.1) 0.041 0.17 (0.12-0.23)   0.003
Stroke  3.83 (1.13-12.93) 0.020 1.18 (0.48-2.86) 0.713 0.62 (0.07-5.22)   0.659  
High alcohol uptake 1.22 (1.22-9.0) 0.013 0.76  (0.73-0.8) 0.081 0.81  (0.75-0.87)   0.337
Neutropenia 2.59 (1.03-6.47) 0.035 0.98 (0.63-1.54) 0.960 2.05 (0.95-4.42)   0.063
Receipt of immunosuppressant 1.19 (0.39-3.61) 0.751 0.56 (0.35-0.89) 0.015 1.27 (0.59-2.74)   0.529
Prior antibiotic use 0.75 (0.17-3.32) 0.706 2.03 (1.32-3.1) 0.001 0.67 (0.21-2.06)   0.485
History of transplantation 0.89 (0.86-0.92) 0.256 0.33 (0.13-0.86) 0.018 1.11 (0.12-10.25)   0.926
PITT score >4 54.07 (20.59-141.96) <0.001 5.96 (3.56-9.99) <0.001 17.21 (6.83-43.36) <0.001
Severe sepsis 10.59 (4.92-22.77) <0.001 7.44 (4.77-11.61) <0.001 5.5 (2.48-12.18) <0.001
Inappropriate empirical antibiotics 6.77 (2.88-15.91) <0.001 2.4 (1.53-3.77) <0.001 6.66 (2.91-15.22) <0.001
Pathogen
   Escherichia coli         
   Fungi 
0.37 (0.17-0.79)
0.89 (0.86-0.93)
0.009
0.633
0.61 (0.32-1.16)
3.44 (0.98-12.1)
0.133
0.041
0.97 (0.43-2.2)
NA        NA
  0.957
NA
Source of infection
   Pneumonia
   Urinary tract infection
3.82 (1.67-8.7)
0.32 (1.12-0.84)
0.001
0.017
4.16 (2.51-6.88)
0.68 (0.25-1.83)
<0.001
0.447
5.25 (2.16-12.77)
0.51 (0.14-1.8)
<0.001
  0.290
CA, community-acquired; HA, hospital-acquired; HCA, healthcare-associated; BSI, bloodstream infection; NA, not available.Son JS, et al.  •  Bloodstream Infection According to the Epidemiologic Type of Infection
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significant risk factors. In HCA-BSI group, underlying congestive 
heart failure was the significant risk factor. For infecting patho-
gens, E. coli was the negative predictive factor for 30-day mortal-
ity in CA-BSI group. Fungal infection was the significant risk fac-
tor for mortality in HA-BSI group. For primary infection, pneu-
monia was the significant risk factor for all patients with BSI.
  By multivariate analysis, high Pitt score (CA-BSI, OR 28.3, P< 
0.001; HA-BSI, OR 2.2, P=0.003; HCA-BSI, OR 7.8, P=0.001) and 
ineffective empirical antibiotic therapy (CA-BSI, OR 5.1, P=0.01; 
HA-BSI, OR 2.2, P=0.003; HCA-BSI, OR 6.0, P=0.001) were the 
common independent risk factors in all patients with BSI (Table 
6). Severe sepsis (OR 5.5, 95% CI 3.2-9.5, P<0.001), pneumonia 
(OR 3.0, 95% CI 1.6-5.6, P<0.001), and prior antibiotic use (OR 
1.7, 95% CI 1.0-2.9, P=0.03) were the independent risk factors in 
patients with HA-BSI.
DISCUSSION
This study was a nationwide surveillance of BSI in Korean hos-
pitals. In this study, we compared clinical and microbiological 
characteristics of 3 types of BSI.
  With regard to prevalent pathogens by the epidemiologic type, 
Gram-negative bacilli (especially E. coli and K. pneumoniae) in 
CA-BSI were due to higher incidence of UTI and intra-abdomi-
nal infection, while Gram-positive cocci (especially staphylo-
cocci) in HA-BSI were due to primary bacteremia which were 
frequently associated with cather-related infection. In HCA-BSI, 
Gram-negative bacilli were also the prevalent pathogen like CA-
BSI, because the incidences of UTI and intra-abdominal infec-
tion were higher than that of primary bacteremia. However, the 
proportion of Gram-negative bacilli in HCA-BSI was differed 
from that in CA-BSI. 
  Cheong et al. (16) previously reported that the prevalence of 
ESBL-producing E.coli in HCA-BSI (6.7%) was higher than that 
in CA-BSI (3.2%), although it did not show the statistical differ-
ence between 2 groups. In addition, Kang et al. (17) reported 
that more than half (63.2%) of community-onset BSIs caused by 
ESBL-producing E. coli were HCA-BSI. Our study also showed 
the similar result that the prevalence of ESBL-producing E. coli 
in HCA-BSI and HA-BSI group was higher than that in CA-BSI. 
With regard to S. aureus bacteremia, previous reports showed 
that the prevalence of MRSA was the highest in in HA-BSI (33.8-
61%) followed by HCA-BSI (29.4-52%) and CA-BSI (11-21.2%) (3, 
10, 18). And, our study also showed the similar result.
  In general, early and appropriate antibiotic therapy signifi-
cantly affects the overall mortality in BSI (19, 20). Previous stud-
ies reported that 10-40% of BSI cases received inappropriate 
empirical therapy, which was more frequent in cases of HA-BSI 
and HCA-BSI (9, 21, 22). Our data was also consistent with this 
finding that initial antibiotic therapy was more frequently inap-
propriate in HA-BSI and HCA-BSI cases than in CA-BSI. Given 
the different pathogens and antimicrobial resistance in HCA-
BSI compared with CA-BSI, empirical antibiotic choice should 
be different in HCA-BSI from those in CA-BSI cases.
  Previously, high severity index on admission and inappropri-
ate empirical antibiotic therapy were known as significant risk 
factors in BSI (16, 19, 23). Pazos et al. (23) reported that septic 
shock, and inappropriate antibiotic therapy were found to be 
risk factors for mortality in overall BSI. And, Cheong et al. (16) 
also reported that high Charlson’s index, high Pitt score, and 
acute renal failure were found to be risk factors for mortality in 
E. coli bacteremia. In our study, high Pitt score and inappropri-
ate empirical antibiotic therapy were shown to be the common 
independent risk factors in every BSI group including HCA-BSI 
on multivariate analysis.
  There is a limitation in this study. Our data were obtained from 
a few university hospitals that might lead to the bias of pathogen 
distribution, antimicrobial resistance or primary infection. 
  In conclusion, the present data suggest that clinical features, 
clinical outcome, and microbiologic features of causative patho-
gens vary by epidemiologic type of BSI. Especially, HCA-BSI 
shows a distinct entity of BSI with its unique epidemiology, mi-
crobiology, and treatment outcomes, which shares more simi-
larity with HA-BSI. The only independent risk factors for mor-
tality associated with HCA-BSI could not be found. However, 
considering the inappropriate empirical antibiotic therapy as a 
major independent risk factor for mortality, clinicians should 
be aware of this category for more appropriate antibiotics based 
on possible resistant pathogens.
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